About Isaac Stoner
Isaac Stoner is CEO and director at MindImmune Therapeutics.
Form D filings also name Isaac Stoner as a president and director at Octagon Therapeutics.
Isaac Stoner first appears on SEC filings in 2018.
Experience
This experience comes from Isaac Stoner's profile and from SEC filings. For roles taken from filings, the years are when the filings name Isaac Stoner in the role, so the role may have started earlier or lasted longer.
MindImmune Therapeutics, Inc. Current
Chief Executive Officer (2025 – Present)
Director
2025 – Present · Kingston, RI
Develops immune-targeting drugs for people with Alzheimer's and other neurodegenerative diseases.
SF
Slater Technology Fund Current
EIR
2025 – Present
KV
KdT Ventures Current
Advisor and LP
2017 – Present
Octagon Therapeutics, Inc.
President and director
Chief Executive Officer (2017 – 2025)
2017 – 2025 · Providence, RI
OT
Operation Thonapa
Co-founder and Expedition Leader
2016 – 2025
PH
PureTech Health
Senior Director
2016 – 2017
ME
Martin Trust Center for MIT Entrepreneurship
Healthcare Sector Practice Leader
2015 – 2016
AG
Action Potential Venture Capital (GlaxoSmithKline)
Summer Associate
2015
F2
Firefly BioWorks (acquired by Abcam, 2015)
VP Product Development
2010 – 2015
I2
Ion Torrent Systems (acquired by Life Technologies, 2010)
Research Engineer
2009 – 2010
GC
Genome Corp
Research Associate
2007 – 2009
Key Colleagues at Startups
The people Isaac Stoner works with at each company, as listed on that company's latest Form D.
MindImmune Therapeutics, Inc. · Form D/A, Mar 5, 2026
Octagon Therapeutics, Inc. · Form D, Feb 12, 2024
TS
Thorne Sparkman
Director
RL
Ronald Lennox
Director